RAD140 Testolone / vosilasarm between a breast-cancer Phase 1 and a consumer safety case layer

01 Names and chemistry

RAD140 is a nonsteroidal selective androgen receptor modulator also known as testolone and, in development naming, vosilasarm / EP0062. It is not enobosarm, not ligandrol, not andarine, and not Cardarine. PubChem identity must agree before a paper is admitted.

Open PubMed counts for RAD140 OR testolone OR vosilasarm were on the order of forty-three indexed records at harvest.

02 Mechanism and preclinical residue

Design and preclinical characterisation papers describe potent anabolic effects on muscle and bone with reduced androgenic liability relative to reference androgens in animal models. A 2025 preclinical assessment asked whether RAD140 adds to functional overload hypertrophy in rat plantaris muscle (PMID 40680216) — an animal design, not a human outcome. Earlier work flagged context-specific effects of AR targeting in ER-positive breast-cancer models; those data motivate oncology protocols, not physique protocols.

03 NCT03088527 — first-in-human breast cancer

ClinicalTrials.gov NCT03088527 is a Phase 1, first-in-human, multi-part study of RAD140 in postmenopausal women with hormone receptor–positive breast cancer. The registry API harvest lists status COMPLETED. The primary purpose is clinical safety, tolerability, and pharmacokinetics of oral RAD140 capsules. A first-in-human Phase 1 publication in clinical breast-cancer literature (DOI 10.1016/j.clbc.2021.08.003) and later vosilasarm / EP0062 conference communications expand that thread; conference ASCO abstracts remain secondary until full texts are admitted.

Oncology Phase 1 safety/PK is not a lean-mass RCT in healthy adults and is not grey-market dosing guidance.

04 Consumer safety case layer

Peer-reviewed case reports document cholestatic liver injury temporally associated with RAD-140-labelled supplements. One 2022 report described a 24-year-old man with cholestatic injury and peak total bilirubin 38.5 mg/dL after five weeks of a product labelled RAD-140 (PMID 36561105). Additional idiosyncratic DILI series include RAD-140 among named SARMs. A 2024 case reported myopericarditis in a 16-year-old boy after a first dose of a product called Testolone / RAD-140 (PMID 39157568). These are uncontrolled exposures; product analytics are often absent; they are adverse-signal literature, not efficacy literature.

05 Anti-doping and metabolism

Equine and human-oriented metabolic studies of RAD140 (and co-studies with S-23) support detection chemistry (PMID 32853476 and related work). That stream is regulatory/market context.

06 Regulatory status

RAD140 / vosilasarm is not FDA-approved for bodybuilding or aging. SARMs are WADA S1 prohibited. FDA consumer warnings on SARM body-building products apply to the retail context.

07 Absences

No large Phase 3 physique or sarcopenia programme for RAD140 was admitted as a peer-reviewed package at harvest. Independent RCTs of grey-market testolone do not exist. Preclinical hypertrophy findings are not human outcomes.

08 Harvest literature map

Deep-harvest strata for RAD140: (1) completed Phase 1 FIH registry package NCT03088527 and the clinical breast-cancer FIH publication trail; (2) preclinical muscle/bone and overload studies; (3) consumer DILI and myopericarditis case reports; (4) equine/human metabolic detection. PubMed open count for RAD140 OR testolone OR vosilasarm was approximately forty-three. Vosilasarm / EP0062 ASCO-style abstracts remain secondary. A 2023 rodent paper reporting negative impacts of RAD140 on skeletal muscle adaptation and frailty metrics (PMID 37758180) sits in tension with anabolic marketing and is recorded here as an animal signal requiring careful reading, not as a human protocol result.

How this document was assembled

Commissioned 5 August 2026 in the Adjacent Compounds / SARMs group and rewritten the same day after a deep research-API harvest (Tavily, Exa, PubMed E-utilities, ClinicalTrials.gov API v2, Camoufox for selected primary pages). Artefacts live under projects/adjacent_compounds_research_2026/deep_harvest/. HOUSE_STYLE governs presentation. PubMed-indexed references are NCBI-resolved.

Evidence handling

Study type is named in the reporting sentence. Animal and in-vitro results are not phrased as human outcomes. Sponsor press is secondary until peer-reviewed full text is admitted. Consumer case reports are grey-market exposure literature unless product analytics accompany the report. Cardarine is never called a SARM.

References

1. Brown AM, Ganjayi MS, Baumann CW. RAD140 (Testolone) negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice. Clin Exp Pharmacol Physiol. 2023;50(12):973-983.
   PMID 37758180 · doi:10.1111/1440-1681.13824
2. Khan S, Fackler J, Gilani A, Murphy S, Polintan L. Selective Androgen Receptor Modulator Induced Hepatotoxicity. Cureus. 2022;14(2):e22239.
   PMID 35340496 · doi:10.7759/cureus.22239 · PMC8929477
3. Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases. Eur J Clin Pharmacol. 2024;80(2):185-202.
   PMID 38059982 · doi:10.1007/s00228-023-03592-3 · PMC10847181
4. Leung K, Yaramada P, Goyal P, Cai CX, Thung I, Hammami MB. RAD-140 Drug-Induced Liver Injury. Ochsner J. 2022;22(4):361-365.
   PMID 36561105 · doi:10.31486/toj.22.0005 · PMC9753945
5. Puskas J, Guda T, Niccoli S, Rathbone CR, Tan-Johnson B, Puskas D, et al.. Preclinical assessment of the selective androgen receptor modulator RAD140 to increase muscle mass and bone mineral density. Physiol Rep. 2025;13(14):e70463.
   PMID 40680216 · doi:10.14814/phy2.70463 · PMC12274021
6. Schwartzman KH, Kohli U, Chaudhuri NR, Hoda M. Myopericarditis Following Use of Selective Androgen Receptor Modifier "RAD-140". JACC Case Rep. 2024;29(15):102423.
   PMID 39157568 · doi:10.1016/j.jaccas.2024.102423 · PMC11328744
7. So YM, Wong JKY, Choi TLS, Prabhu A, Stewart B, Farrington AF, et al.. Metabolic studies of selective androgen receptor modulators RAD140 and S-23 in horses. Drug Test Anal. 2021;13(2):318-337.
   PMID 32853476 · doi:10.1002/dta.2920
8. Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019;7(1):84-94.
   PMID 30503797 · doi:10.1016/j.sxmr.2018.09.006 · PMC6326857
9. ClinicalTrials.gov. NCT03088527 — Phase 1 first-in-human RAD140 in postmenopausal women with HR+ breast cancer. Protocol inventory.
   https://clinicaltrials.gov/study/NCT03088527
10. U.S. Food and Drug Administration. Consumer updates and warning letters on body-building products containing SARMs. Regulatory context.
    https://www.fda.gov/
11. World Anti-Doping Agency. Prohibited List — S1 Anabolic Agents (selective androgen receptor modulators).
    https://www.wada-ama.org/
12. NIDDK LiverTox. Selective Androgen Receptor Modulators (SARMs). NCBI Bookshelf NBK619971.
    https://www.ncbi.nlm.nih.gov/books/NBK619971/
13. ClinicalTrials.gov. Protocol inventory via API v2; not peer-reviewed results.
    https://clinicaltrials.gov/
14. PubChem compound summary pages used for identity cross-checks.
    https://pubchem.ncbi.nlm.nih.gov/